---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021181"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:15:00.330216+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q1 net product revenue $71.4M; net income $1.6M vs $47.8M loss YoY

## Summary
- Net product revenue $71.4M from RELYVRIO/ALBRIOZA ALS sales; cost of sales $5.3M.
- Net income $1.6M ($0.02/share) vs net loss $47.8M ($0.93/share) in Q1 2022.
- Cash and investments $345.7M at March 31, 2023, down slightly from $346.9M at Dec 31, 2022.
- Phase 3 PHOENIX ALS trial fully enrolled (664 participants); topline results expected mid-2024.
- Plans to initiate global Phase 3 trial of AMX0035 in progressive supranuclear palsy in 2023.

## SEC filing metadata
- accession: 0000950170-23-021181
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/0000950170-23-021181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/amlx-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021181
- JSON: https://secwatch.observer/filing/0000950170-23-021181.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021181.txt

## Key facts
- Earnings Releases
  Amylyx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: revenue $71.4 million, net income $1.6 million, or $0.02 per share, EPS $0.02 per share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $71.4 million
  - Net income: $1.6 million, or $0.02 per share
  - EPS: $0.02 per share
  - Result: reported results
  source text: in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO ® in U.S. and ALBRIOZATM in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/0000950170-23-021181-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.